Clearmind Medicine Inc. CMND
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -95.91%
- 1 year
- -99.77%
- Market cap
- 3.00M
- EPS (ttm)
- -461.20
- Shares out
- 4.38M
- YTD return
- -95.91%
- 1-year return
- -99.77%
- Volume
- 4.68K
- Avg volume
- 57.83K
- Open
- 5.81
- Previous close
- 6.14
- Day's range
- 5.43 – 6.10
- 52-week range
- 5.25 – 2,624.00
- Beta
- -1.51
YTD -153.20 (-96.23%)
Key statistics
- Enterprise value
- -2.75M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 162.86K
- Total cash
- 7.68M
- Total debt
- 60.90K
- Return on equity
- -267.90%
- Short % of float
- 4.72%
- 50-day average
- 1.39
- 200-day average
- 1.33
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr. Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- clearmindmedicine.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder 
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial 
Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform 
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets 
Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia 
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder 
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA 
Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026 
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Your note
Sign in to keep a note on CMND — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gotham Asset Management, LP | 10.70% | 339,008 | 413.59K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 5.38% | 170,641 | 208.18K | Sep 29, 2024 |
| UBS Group AG | 4.46% | 141,337 | 172.43K | Sep 29, 2024 |
| Cornerstone Wealth Group, LLC | 0.63% | 20,000 | 24.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.56% | 17,729 | 21.63K | Sep 29, 2024 |
| HRT Financial LP | 0.40% | 12,756 | 15.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.74% | 213,764 | 260.79K | Oct 30, 2024 |